Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

GALVUS 50 mg COMPRIMIDOS - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/GALVUS 50 mg COMPRIMIDOS

Approved

STANDARD

GALVUS 50 mg COMPRIMIDOS

Novartis Europharm Limited🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Feb 15, 2021
Approval ID: 91a3bde20aca02a7
Company: Novartis Europharm Limited
Type: Standard

Approval Details

Approval Id: 91a3bde20aca02a7
Drug Cima Aemps Name: GALVUS 50 mg COMPRIMIDOS
Register Number: 07414003IP
Holder Company Name: Novartis Europharm Limited
Marketing Company Name: Difarmed S.L.
Holder Company Detail Path: /organization/novartis-europharm-limited
Authorization Date: 2021-02-15
Dosage Form: COMPRIMIDO
Dose: 50mg
Route Of Administration: VÍA ORAL
Prescription Type: Medicamento Sujeto A Prescripción Médica
Commercialized: Yes
Company Name: Novartis Europharm Limited
Company Detail Path: /organization/novartis-europharm-limited

Company Information

Pharmaceutical Company Name: NOVARTIS EUROPHARM LIMITED
Country Name: United Kingdom
City Name: camberley,country_gb
Address: 200 Frimley Business Park

Active Ingredients

VILDAGLIPTINA

50 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Feb 15, 2021

Approval ID

91a3bde20aca02a7

Type

Standard

Back to CIMA-AEMPS Approvals